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The quantity of mRNA transcripts in a cell is determined by a complex interplay of cooperative and counteracting
biological processes. Independent Component Analysis (ICA) is one of a few number of unsupervised algorithms that
have been applied to microarray gene expression data in an attempt to understand phenotype differences in terms of
changes in the activation/inhibition patterns of biological pathways. While the ICA model has been shown to
outperform other linear representations of the data such as Principal Components Analysis (PCA), a validation using
explicit pathway and regulatory element information has not yet been performed. We apply a range of popular ICA
algorithms to six of the largest microarray cancer datasets and use pathway-knowledge and regulatory-element
databases for validation. We show that ICA outperforms PCA and clustering-based methods in that ICA components
map closer to known cancer-related pathways, regulatory modules, and cancer phenotypes. Furthermore, we identify
cancer signalling and oncogenic pathways and regulatory modules that play a prominent role in breast cancer and
relate the differential activation patterns of these to breast cancer phenotypes. Importantly, we find novel associations
linking immune response and epithelial–mesenchymal transition pathways with estrogen receptor status and
histological grade, respectively. In addition, we find associations linking the activity levels of biological pathways and
transcription factors (NF1 and NFAT) with clinical outcome in breast cancer. ICA provides a framework for a more
biologically relevant interpretation of genomewide transcriptomic data. Adopting ICA as the analysis tool of choice will
help understand the phenotype–pathway relationship and thus help elucidate the molecular taxonomy of
heterogeneous cancers and of other complex genetic diseases.
Citation: Teschendorff AE, Journe´e M, Absil PA, Sepulchre R, Caldas C (2007) Elucidating the altered transcriptional programs in breast cancer using Independent Component
Analysis. PLoS Comput Biol 3(8): e161. doi:10.1371/journal.pcbi.0030161
Introduction
Microarray technology is enabling genetic diseases like
cancer to be studied in unprecedented detail, at both
transcriptomic and genomic levels. A signiﬁcant challenge
that needs to be overcome to further our understanding of
the relation between the quantitative transcriptome of a
sample/cell and its phenotype is to unravel the complex
mechanism that gives rise to the measured mRNA levels. The
amount of a given mRNA transcript in a normal sample/cell is
determined by a whole range of biological processes, some of
which (e.g., transcription repression and degradation) act to
reduce this number, while others (e.g., transcription factor
induction) act to increase it. Therefore, it is natural to model
the level of a given mRNA transcript as the net sum of a
complex superposition of cooperating and counteracting
biological processes, and, furthermore, to assume that disease
is caused by aberrations in the activation patterns of these
biological processes that upset the delicate balance between
expression and repression in otherwise healthy tissue. Many
distinct biological mechanisms that underlie the aberrations
observed in human cancer have been identiﬁed, most notably
copy-number changes [1] and epigenetic changes [2], yet it is
the effect that these changes have downstream on the
functional pathways that ultimately dictates whether these
changes are pathological or not.
While several studies have recently characterised the
altered functional pathways and transcriptional regulatory
programs in human cancer, they have done so either by
interrogating the expression data directly with previously
characterised pathways, regulatory modules [3–6], and func-
tionally related gene lists [7], or by interrogating derived
‘‘supervised’’ lists of genes for enrichment of biological
function [8]. Hence, these studies have not attempted to infer
the altered biological processes, which putatively map to
alterations of known functional pathways and transcriptional
regulatory programs. Thus, an unsupervised method that ﬁrst
infers the underlying altered biological processes and then
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relates these to aberrations in pathways or regulatory module
activity levels is desirable.
A necessary property of such an algorithm is that it allows
‘‘gene-sharing,’’ so that a speciﬁc gene can be part of multiple
distinct pathways. In this regard, it is worth noting that
popular approaches for analysing transcriptomic data, such
as hierarchical or k-means clustering, do not allow for genes
to be shared by multiple biological processes, since they place
a gene in a single cluster [9], and so they are not tailored to
the problem of inferring altered pathways.
Algorithms that allow genes to be part of multiple
processes/clusters have also been extensively applied [10–
12]. Among these, Singular Value Decomposition (SVD) or
Principal Components Analysis (PCA) provides a linear
representation of the data in terms of components that are
linearly uncorrelated [12]. While this linear decorrelation of
the data covariance matrix can uncover interesting biological
information, it is also clear that it fails to map the
components into independent biological processes, since
there is no requirement for PCA components to be statisti-
cally independent. Mapping the data to independent bio-
logical processes, whereby independence is measured using a
statistical criterion, should provide a more realistic repre-
sentation of the data, since it explicitly recognises how the
data was generated in the ﬁrst place. This assumption, which
is to be tested a posteriori, underlies the application of
Independent Component Analysis (ICA) to gene expression
data [13,14]. Speciﬁcally, ICA decomposes the expression data
matrix X into a number of ‘‘components’’ (k¼ 1,2,..K), each of
which is characterised by an activation pattern over genes (Sk)
and another over samples (Ak) (Figure 1 and Materials and
Methods),
X ¼
XK
k¼1
Sk  Ak þ E ð1Þ
in such a way that the gene activation patterns (S1,S2,. . .,SK)
are as statistically independent as possible while also
minimising the residual ‘‘error’’ matrix E (in the above, 
denotes the Kronecker tensor product). It is worth noting
that while ICA also provides a linear decomposition of the
data matrix, the requirement of statistical independence
implies that the data covariance matrix is decorrelated in a
non-linear fashion, in contrast to PCA where the decorrelation
is performed linearly.
Many studies have shown the value of ICA in the gene
expression context as a dimensional reduction and gene-
functional discovery tool [15–20] and also as a potential tool
for classiﬁcation and diagnosis [21,22]. To validate the ICA
model, most of these studies used the Gene Ontology (GO)
framework [23]. However, GO does not provide the best
framework in which to evaluate the ICA paradigm, since
many genes with the same GO term annotation may not be
part of the same biological pathway or may not be under the
control of the same regulatory motif, and vice versa. In fact,
to date no study has evaluated the ICA paradigm in the
explicit context of biological pathways and regulatory
modules.
In this work we apply various popular ICA algorithms to six
of the largest available microarray cancer datasets. We focus
on breast cancer for two reasons. First, for this type of cancer
many large patient cohorts that have been proﬁled with
microarrays are available. Second, breast cancer is a highly
heterogeneous disease and hence it provides a more
challenging (and hence suitable) arena in which to compare
and evaluate different methodologies. We also use two large
microarray datasets from two other cancer types to show that
our results are valid more generally. The aim of our work is 2-
fold. First, to test the ICA paradigm by showing that it
signiﬁcantly outperforms both a gene-sharing method that
does not use the statistical independence criterion (PCA) and
a traditional (‘‘non–gene-sharing’’) clustering method (k-
means). We achieve this by using a pathway and regulatory
module–based framework for validation. The second aim is to
ﬁnd the most frequently altered pathways and regulatory
modules in human breast cancer and to explore their
relationship to breast cancer phenotypes.
Results
Testing the ICA Paradigm
The main modelling hypothesis underlying the application
of ICA to gene expression data is that the expression level of a
gene is determined by a linear superposition of biological
processes, some of which try to express it, while other
contending processes try to suppress it (Figure 1). It is
assumed that these biological processes correspond to
activation or inhibition of single pathways or sets of highly
correlated pathways, and that each of these pathways only
affects a relatively small percentage of all genes. Because of
the statistical independence assumption inherent in the ICA
inference process, we would expect the identiﬁed independ-
ent components to map more closely to known pathways than
an alternative linear decomposition method, like PCA, that
does not use the statistical independence criterion. Similarly,
we would expect ICA components to map closer to pathways
than clusters derived from popular clustering algorithms such
as k-means or hierarchical clustering.
To test the modeling hypothesis of ICA for expression
data, we ﬁrst asked how well the inferred components
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Author Summary
The amount of a given transcript or protein in a cell is determined
by a balance of expression and repression in a complex network of
biological processes. This delicate balance is compromised in
complex genetic diseases such as cancer by alterations in the
activation patterns of functionally important biological processes
known as pathways. Over the last years, a large number of
microarray experiments profiling the expression levels of more than
20,000 human genes in hundreds of tumor samples have shown
that most cancer types are heterogeneous diseases, each charac-
terized by many different expression subtypes. The biological and
clinical goal is to explain the observed tumor and clinical
heterogeneity in terms of specific patterns of altered pathways.
The bioinformatic challenge is therefore to devise mathematical
tools that explicitly attempt to infer these altered pathways. To this
end, we applied a signal processing tool in a meta-analysis of breast
cancer, encompassing more than 800 tumor specimens derived
from four different patient cohorts, and showed that this algorithm
significantly outperforms popular standard bioinformatics tools in
identifying altered pathways underlying breast cancer. These results
show that the same tool could be applied to other complex human
genetic diseases to better elucidate the underlying altered path-
ways.
Elucidating the Altered Transcriptional Programs
Figure 1. The ICA Model of Gene Expression
Schematic depiction of the ICA model for gene expression.
(A) Measured gene expression variations are caused by alterations in the activation levels of biological pathways. In the ICA model, the gene expression
matrix is decomposed into the product of a ‘‘source’’ matrix S and a ‘‘mixing’’ matrix A, where K is the number of inferred independent components (IC)
to which pathways and regulatory modules map. The columns of S describe the activation levels of genes in the various inferred independent
components, while the rows of A give the activation levels of the independent components across tumor samples. The product of S and A can be
written as a sum over the IC submatrices IC-1,IC-2,...IC-K.
(B) IC–k–submatrix is obtained by multiplying the k-th column of S, Sk, with the k-th row of A, Ak. The genes with the largest absolute weights in Sk are
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mapped to known pathways, as curated in the MSigDB
pathway database [24] (Materials and Methods, Table S1).
This strategy was initially applied to a total of six breast
cancer microarray datasets (‘‘Perou’’ [25], ‘‘JRH-1’’ [26],
‘‘Vijver’’ [27], ‘‘Wang’’ [28], ‘‘Naderi’’ [29], ‘‘JRH-2’’ [30]),
summarised in Table 1, and for four different implementa-
tions of the ICA algorithm (‘‘fastICA’’, ‘‘JointDiag’’, ‘‘Kernel-
ICA’’, and ‘‘Radical’’) [31–34] as well as for ordinary PCA and
two versions of k-means clustering (PCA-KM and MVG-KM)
(Materials and Methods and Protocol S1). For each of the ICA
algorithms and PCA, we inferred ten components and
selected the genes based on their weights in the correspond-
ing column of the source matrix S (Materials and Methods).
The average number of genes selected per component
ranged from 50 to 200 depending on the cohort (Table S2).
For the two k-means clustering algorithms, ten gene clusters
were inferred on subsets of most variable genes to ensure
that the average number of genes per cluster was similar to
that of the PCA and ICA components. This step was
necessary to ensure an objective comparison of the different
algorithms. In what follows we also use the term component
to denote clusters. To evaluate how close the inferred
components of a given algorithm in a particular cohort
mapped to existing pathways, we deﬁned a pathway enrich-
ment index, PEI, as follows. For each component i and
pathway p, we ﬁrst evaluated the signiﬁcance of enrichment
of genes in that pathway in the selected feature set of the
component by using the hypergeometric test (see Materials
and Methods). This yielded for each component i and
pathway p a p-value Pip. Correction for multiple testing was
done using the Benjamini-Hochberg procedure to obtain an
estimate for the false discovery rate (FDR). A component i
was then declared enriched for a pathway p if the Benjamini-
Hochberg corrected p-value was less than 0.05. Hence, we
would expect approximately 5% of signiﬁcant tests to be
false positives. Finally, we counted the number of pathways
enriched in at least one component and deﬁned the PEI as
the corresponding fraction of enriched pathways.
ICA Components Map Closer to Known Biological
Pathways
The PEI for each of the seven methods (‘‘PCA’’, ‘‘MVG-
KM’’, ‘‘PCA-KM’’, ‘‘fastICA’’, ‘‘JointDiag’’, ‘‘KernelICA’’,
‘‘Radical’’, and ‘‘PCA’’) and the four largest breast cancer
sets (‘‘Vijver’’, ‘‘Wang’’, ‘‘Naderi’’, ‘‘JRH-2’’) are shown in
Figure 2A (the results for all six breast cancer cohorts are
presented in Figure S1). This showed that across the four
major cohorts the PEI was higher for ICA algorithms when
compared with PCA and the clustering-based methods.
Interestingly, for the two largest cohorts (‘‘Vijver’’ and
‘‘Wang’’), the degree of improvement in the PEI of ICA over
PCA, MVG-KM, and PCA-KM was highest. In contrast, for the
smaller cohorts (e.g., ‘‘Perou’’ and ‘‘JRH-1’’), the degree of
improvement of ICA over PCA or KM was less marked.
Hence, since we found that cohort size had a signiﬁcant
impact on the inferred components, we restricted all
subsequent analysis to the four major breast cancer cohorts.
It is also noteworthy that when comparing the various ICA
algorithms with each other we didn’t observe any appreciable
difference in their respective PEI.
ICA Captures More Cancer Signalling and Oncogenic
Pathways in Breast Cancer
To investigate this further, we next compared the algo-
rithms on the subset of nine cancer-signalling pathways from
the curated resource NETPATH (http://www.netpath.org) and
ﬁve oncogenic pathways [35]. These are pathways that are
frequently altered in cancer and hence we would expect many
of these to be captured by the ICA algorithm. Thus, for each
method and study we counted the number of pathways that
were enriched in any of the components (Figure 2B). This
showed that in the three largest breast cancer studies
(‘‘Vijver’’, ‘‘Wang’’, and ‘‘Naderi’’), PCA and the KM-methods
captured the least number of pathways. In the two largest
cohorts (‘‘Vijver’’ and ‘‘Wang’’), for example, the ‘‘RADICAL’’
ICA algorithm captured ten and six of the 14 pathways, while
PCA captured eight and two pathways, respectively.
ICA-Derived Components Map Closer to Regulatory
Modules
As a further validation that ICA outperforms PCA, we
investigated the relation of the derived components with
regulatory modules. Speciﬁcally, we tested the selected gene
sets from each component for enrichment of genes with
common regulatory motifs in their promoters and 39 UTRs
[36]. Under the ICA paradigm we would expect genes that are
under the common regulatory control of a transcription
factor to appear in the same ICA component. Thus, for each
breast cancer cohort and method we counted the number of
regulatory motifs whose associated genes were overrepre-
sented in components (Figure 2C), using as before the
hypergeometric test to test for signiﬁcant enrichment
(Materials and Methods). This showed that PCA performed
worst out of all algorithms. In two cohorts (‘‘Wang’’ and
‘‘Naderi’’), none of the PCA components was associated with
any of the 173 distinct regulatory motifs. In contrast, the
Table 1. Breast Cancer Cohorts
Study Platform Genes Samples Tissue
Perou cDNA 7,497 84 Breast
JRH-1 cDNA 4,167 99 Breast
Vijver Agilent oligo 13,319 295 Breast
Wang Affymetrix 14,913 285 Breast
Naderi Agilent oligo 8,278 135 Breast
JRH-2 Affymetrix 14,223 101 Breast
Hummel Affymetrix 13,266 221 Lymphoma
Chen cDNA 14,580 132 Gastric
For each study, we give the type of microarray platform used, the number of good quality
gene spots on the array, the number of profiled tumours, and the tumour type.
doi:10.1371/journal.pcbi.0030161.t001
selected and tested for enrichment of biological pathways, while the distribution of weights in Ak are tested for discriminatory power of phenotypes.
(Colour codes for heatmaps: red, overexpression; green, underexpression; blue, upregulation; yellow, downregulation.)
doi:10.1371/journal.pcbi.0030161.g001
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components derived by ICA algorithms were consistently
associated with regulatory motifs. Interestingly, the improve-
ment of ICA over KM-based methods was less marked with
only study (‘‘Wang’’) showing a substantial improvement
(Figure 2C).
ICA Outperforms PCA and KM-Clustering across Different
Cancer Types
The results above show that ICA provided a more
biologically meaningful decomposition of breast cancer
expression data than PCA or KM-based methods. This
suggested to us that similar results would hold in other types
of cancer. To check this, we analysed two additional large
microarray datasets, one proﬁling 221 lymphomas [37]
(‘‘Hummel’’) and another proﬁling 132 gastric cancers [38]
(‘‘Chen’’) (see Table 1). The same analysis on these two
additional datasets conﬁrmed that the PEI was higher for ICA
when compared with PCA or KM-clustering methods (Figure
2A), and that ICA components also mapped closer to known
regulatory motifs (Figure 2C).
ICA Provides a More Robust Identification of Differentially
Activated Biological Pathways and Regulatory Modules in
Breast Cancer
To investigate the robustness of the algorithms, we next
compared the ability of the algorithms to identify pathways
and regulatory modules that were differentially activated
independent of the breast cancer cohort used. Two important
observations that were independent of the ICA algorithm and
cohort used could be derived from the heatmaps of differ-
ential activation of pathways and regulatory modules (Figures
S2–S5). First, ICA identiﬁed many more pathways that were
consistently differentially activated across all four breast
cancer cohorts (Figure 3A). This further conﬁrmed that the
associations between components and pathways as picked out
Figure 2. Testing the ICA Paradigm
(A) For each cohort and method, we give the pathway enrichment index, PEI, defined by the fraction of biological pathways (536 in total) found
enriched in at least one component.
(B) For each cohort and method, we give the fraction of cancer-signalling and oncogenic pathways (14 in total) successfully mapped by the inferred
components.
(C) For each cohort and method, we give the fraction of motif-regulatory gene sets (173 in total) captured by the inferred components.
doi:10.1371/journal.pcbi.0030161.g002
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by ICA were more robust and consistent between cohorts
than those identiﬁed through PCA, MVG-KM, or PCA-KM.
Among the pathways that were found to map most frequently
and consistently to components were those related to
estrogen signalling as well as to other important breast
cancer–signalling pathways such as the EGFR1 and TGF-b
pathways (Figures 3B and S2–S5). We also found cell-
adhesion, immune-response, cell-cycle, and metabolic path-
ways to be commonly differentially activated across the
cohorts. While breast cancer studies have found study-speciﬁc
gene clusters associated with cell-cycle, estrogen-response,
cell-adhesion, and immune-response functions, our results
show that expression variation across breast tumours can be
understood in terms of single pathways (i.e., a ﬁxed common
set of genes for all studies) that relate to these biological
functions.
Figure 3. Most Consistent and Frequently Mapped Pathways and Regulatory Motifs
(A) For each method, we compare the number of pathways that were consistently mapped to components across the four major breast cancer studies.
(B) Twenty of the most frequently mapped pathways by ICA. The scores give the average number of ICA components in which the pathway was
mapped.
(C) For each method, we give the number of motif-regulatory gene sets consistently mapped to components across the four major breast cancer
cohorts.
(D) The 20 most frequently mapped transcription factors/regulatory motifs by ICA. The scores give the average number of ICA components in which the
regulatory module of the motif was mapped.
doi:10.1371/journal.pcbi.0030161.g003
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Second, we also observed that ICA outperformed PCA,
MVG-KM, and PCA-KM in identifying regulatory modules
that were consistently differentially activated across cohorts
(Figure 3C). Speciﬁcally, the KernelICA algorithm identiﬁed
the regulatory modules TATA, AACTTT, NFAT, IRF, and
NF1, while MVG-KM only picked out TATA, with PCA and
PCA-KM failing to capture any regulatory module. Among
the motifs with regulatory gene modules that were most
frequently captured by independent components, we found
several with important general (e.g., TATA) and speciﬁc
transcription factors (e.g., NF1 and ETS2) (Figures 3D and S2–
S5).
Differentially Activated Pathways and Regulatory Modules
Associate with Breast Cancer Phenotypes
We next asked whether components mapping into the
various pathways/modules were associated with breast cancer
phenotypes. Speciﬁcally, we considered three categorical
phenotypes: estrogen receptor (ER) status (0,1), histological
grade (1,2,3), and outcome (0,1). To evaluate statistical
signiﬁcance of any association between a component k and
phenotype, we considered the distribution of weights from
the corresponding row of the mixing matrix, i.e., Ak (Materials
and Methods), across the different categories. We used the
Wilcoxon rank-sum test for the two binary phenotypes and
the Kruskal-Wallis test for histological grade. Because of the
clustering nature of the MVG-KM and PCA-KM algorithms,
in these two cases we ﬁrst applied k-means over the genes in
the cluster to partition the samples into two groups and
subsequently used Fisher’s exact test to determine whether
the phenotype distribution across the two groups was
signiﬁcantly different from random or not.
This revealed a complex pattern of signiﬁcant associations
with several components differentiating breast tumours
according to ER status and histological grade (Figures S2–
S5). It is notable that in all cohorts ICA components
associating with clinical outcome were also found, while
PCA generally did not. Another feature was the fact that
more and stronger phenotype associations were uncovered by
using ICA as compared with PCA. On the other hand, MVG-
KM performed as well as ICA in mapping to ER, grade, and
outcome phenotypes.
Since we characterised each component in terms of the
differential activation pattern of cancer-related pathways
and regulatory modules, for those components associated
with a phenotype we were able to link the corresponding
pathways and regulatory motifs with the phenotype (Figure
4). This led to several well-known but also novel observa-
tions. First, as expected, ICA components that were strongly
associated with ER status were frequently mapped to the
estrogen signalling pathway. Second, ICA components that
mapped to the CR (cancer related) cell-cycle pathway [39]
were frequently associated with either grade or outcome.
The association between cell-cycle genes and grade or
outcome is well-known [26,30,40], and our ﬁnding further
shows that an independently characterised cell-cycle path-
way associates with these clinical variables across multiple
studies. Third, we observed that pathways relating to
immune response functions and the classical complement
pathway were frequently correlated with ER status, grade,
and, although less frequently, with clinical outcome. For
example, we found in each of the four major breast cancer
cohorts an ICA component that mapped to the CR immune
response pathway [39], and which was consistently over-
activated in ER relative to ERþ tumours (Figure 5A and
Table 2). We note that the same set of genes, when viewed
over the measured expression matrix also separated the
samples according to ER status (Figure 5B and Table 2).
Fourth, in all studies where grade information was available,
an ICA component mapping to either matrix-metallopro-
teinases (MMP) or the cell-adhesion pathway was found to
be associated with histological grade. In three studies
(‘‘Wang’’, ‘‘Vijver’’, and ‘‘Naderi’’), the MMP pathway was
also found to be associated with outcome. Another
interesting pathway we found to be associated with
histological grade was an epithelial–mesenchymal transition
(EMT) signalling pathway characterised in [41]. Speciﬁcally,
ICA revealed a component driving upregulation of genes
involved in EMT in poorly differentiated tumours relative to
low-grade tumours across the three studies where grade
information was available (Figure 6A and Table 3). When the
same set of genes deﬁning the EMT pathway was viewed
over the measured expression matrix, their pathway
coherence was less evident, although the association with
grade was still revealed by k-means clustering (Figure 6B and
Table 3).
The parallel analysis for regulatory motifs and breast
cancer phenotypes provided direct links between the
associated transcription factors and clinical variables (Figure
4B). Strikingly, we found that the interferon regulatory factor
(IRF) showed the strongest associations with both the ER and
grade phenotypes. The regulatory module associated with the
TATA box was also frequently associated with ER, grade, and
outcome. Interestingly, we found differential activation of the
regulatory modules associated with the neuroﬁbromin-1
(NF1), NFAT, and ETS2 transcription factors to be associated
with clinical outcome, which is signiﬁcant in view of the
results of several recent studies linking these transcription
factors with the metastatic and cell-growth properties of
breast cancer cells [42–46].
It is important to point out that ICA facilitated the
identiﬁcation of many of the biological associations in
comparison with PCA, MVG-KM, and PCA-KM (Figure 7).
Thus, for example, we can see that the association between
immune response and ER status was found in all cohorts by
any one of the four ICA algorithms, whereas PCA and the KM
methods were generally not as robust (Figure 7A). A similar
observation could be made for the associations between the
EMT pathway and grade, and that of the IRF module and ER
status (Figure 7B and 7C). For the case of NF1 and clinical
outcome, this association was not identiﬁed by PCA or the
KM-based methods (Figure 7D).
Finally, we veriﬁed that in many cases the identiﬁed
associations were independent, in the sense that the compo-
nent(s) or genes linking a pathway with a phenotype could be
different from the one(s) linking another pathway with the
same phenotype. For example, we noted that this was the case
for the associations of the cell-adhesion and estrogen-signal-
ling pathways with grade (see Figures S2 and S4). Similarly, the
associations of the immune response pathway and IRF module
with ER status (Figure 7A and 7C) could not be attributed to a
common gene subset selection, since the pathway and module
gene sets shared no genes in common.
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Association Networks
Networks are a useful tool for graphically representing
relational structures between many layers of organisation. In
our application, we sought to construct a network of
associations, linking breast cancer phenotypes, pathways,
and regulatory modules with each other as the nodes in the
network. To represent only the most salient and robust
features, we focused attention on those pathways and
regulatory modules with most phenotypic associations (Fig-
ure 4) and on those associations that were most consistently
predicted across cohorts. Thus, we constructed an average
network over the networks for each study by deﬁning a link
between any two nodes in the network if there were at least
three studies in which there was a link between the two nodes,
as predicted by ICA (Figure 8) (KernelICA was used but the
other ICA algorithms gave similar networks). This revealed a
complex network of associations between transcription
factors, pathways, and breast cancer phenotypes. Strengthen-
ing the association of immune response with ER status
further, we found triangular relationships involving the NF-
jb, ETS2, and IRF transcription factors (Figure 8A), which is
plausible in view of their role in regulating immune response
pathways [47–49]. The corresponding network for clinical
outcome showed that apart from the cell-cycle and estrogen-
signalling pathways, only the EGFR1 and TGF-b pathways
were consistently associated with outcome (Figure 8B).
Discussion
In our view, it is most natural to analyse gene expression
data in the context of a generative model, however
approximate this model is to the true underlying mechanism
that gives rise to the measured expression levels. ICA provides
such a generative model since it explicitly recognises how the
data was generated in the ﬁrst place. By comparing ICA with
PCA and clustering-based methods, we have shown that a
more realistic representation of the data is obtained by
allowing ‘‘gene-sharing’’ and using the statistical independ-
Figure 4. Heatmaps of Association of Pathways and Regulatory Modules with Breast Cancer Phenotypes
For three phenotypes (ER, Grade, Outcome), we show heatmaps of association between phenotypes and selected pathways (A) and selected regulatory
motifs (B), as revealed by the four ICA algorithms across the four major breast cancer cohorts. For phenotypes, we used a p-value threshold of 0.05 to
establish whether an ICA component was associated with that phenotype. For pathways and regulatory modules, we used the Benjamini corrected p-
values as before. For each cohort, we then counted the number of ICA algorithms that found a component linking a phenotype with a pathway/
regulatory module, which was colour-coded as 4 (dark red), 3 (red), 2 or 1 (pink), and 0 (white). For Wang’s cohort, grade information was unavailable
and is colour-coded as grey.
doi:10.1371/journal.pcbi.0030161.g004
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ence criterion (non-linear decorrelation) in the inference
process (ICA), as opposed to not allowing gene-sharing
(MVG-KM, PCA-KM) and only using a linear decorrelation
criterion (PCA). We showed this on a total of six cancer
microarray datasets, using existing pathway knowledge and
gene regulatory module databases for evaluation. Speciﬁcally,
we found that ICA components mapped closer to cancer-
related pathways as well as to gene modules that are under
the control of a common regulatory motif. It is worth
pointing out though that the improvement of ICA over KM
methods was less marked in the case of regulatory motifs, as
we would expect, since a clustering method is partially
tailored to ﬁnding co-regulatory structure. Importantly, when
comparing the results across cohorts, we found that ICA
algorithms were much more robust than PCA or KM-based
methods, in the sense that pathways that were found to be
differentially activated through ICA in one cohort were also
consistently differentially activated in the other cohorts. A
similar observation could also be made for the regulatory
motifs and their regulatees. For example, using PCA or PCA-
KM, no regulatory module was found to be differentially
Figure 5. The Association of Immune Response with Estrogen Receptor Status
(A) For each major breast cancer cohort, we give the heatmap of component expression values for the component enriched for the immune-response
pathway characterised in [39]. Thus, the heatmap matrix shown is SgkAks where k is the component enriched for the immune response pathway, g is any
gene found on the array that is also in the pathway and the selected feature set of the component, and s denotes the tumour sample. Samples have
been ordered according to a k-means (k ¼ 2) clustering over the set of genes. The ICA algorithm for which this heatmap is shown is the KernelICA
algorithm. Blue denotes ‘‘upregulation,’’ yellow ‘‘downregulation.’’ For the samples, black denotes an ER and grey an ER þ tumour.
(B) For each major breast cancer cohort, we give the heatmap of expression values for the same set of genes as in (A). Thus, the heatmap matrix shown
is Xgs where Xgs denotes the measured expression level of gene g in sample s. As before, samples have been ordered according to a k-means (k¼ 2)
clustering over the represented genes. Red denotes relative overexpression, green underexpression. Magenta denotes the upregulated cluster, cyan the
downregulated cluster.
doi:10.1371/journal.pcbi.0030161.g005
Table 2. Association of Immune Response with Estrogen
Receptor Status
Matrix Vijver Wang Naderi JRH-2
IC ER ERþ ER ERþ ER ERþ ER ERþ
‘‘Down’’ 16 138 28 127 17 73 13 53
‘‘Up’’ 53 88 49 81 23 20 11 19
p-Value ,107 0.0003 ,104 0.12
EXP ER ERþ ER ERþ ER ERþ ER ERþ
‘‘Down’’ 10 82 34 144 23 79 14 57
‘‘Up’’ 59 144 43 64 17 14 10 15
p-Value 0.0005 0.0002 0.001 0.06
For each major cohort where ER information was available, we give the ER distribution of
the tumours across the ‘‘upregulated’’ and ‘‘downregulated’’ IR clusters as predicted by k-
means clustering over the matrices SgkAks (IC) and Xgs (EXP), where g denotes the genes of
the IR pathway which are also in the selected feature set of the IR-enriched independent
component k, and s denotes the samples. Tabulated p-values were computed using
Fisher’s test.
doi:10.1371/journal.pcbi.0030161.t002
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activated across all four major breast cancer studies, while the
ICA algorithms found an average of four modules. The most
likely explanation for the relatively smaller number of
regulatory modules found in common across the four studies,
as compared with pathways, is that many regulatory modules
important to breast cancer have yet to be elucidated.
Of note, we also performed the enrichment analysis of the
independent components for chromosomal bands (using the
Figure 6. The Association of Epithelial–Mesenchymal Transition with Histological Grade
(A) For each major breast cancer cohort where grade information was available, we give the heatmap of component expression values for the
component enriched for the EMT pathway characterised in [41]. Thus, the heatmap matrix shown is SgkAks where k is the component enriched for the
EMT pathway, g is any gene found on the array that is also in the pathway and the selected feature set of the component, and s denotes the tumour
sample. The ICA algorithm for which this heatmap is shown is the KernelICA algorithm. Samples have been ordered according to a k-means (k ¼ 2)
clustering over the set of genes. Blue denotes ‘‘upregulation,’’ yellow ‘‘downregulation.’’ For the samples, histological grade is colour-coded as black
(high-grade), blue (intermediate grade), and skyblue (low-grade).
(B) For each major breast cancer cohort, we give the heatmap of expression values for the same set of genes as in (A). Thus, the heatmap matrix shown
is Xgs where Xgs denotes the measured expression level of gene g in sample s. As before, samples have been ordered according to a hierarchical
clustering over the represented genes. Red denotes relative overexpression, green underexpression. Magenta denotes the upregulated cluster, cyan the
downregulated cluster.
doi:10.1371/journal.pcbi.0030161.g006
Table 3. Association of Epithelial–Mesenthymal Transition with Grade
Matrix Vijver Naderi JRH-2
Low Intermediate High Low Intermediate High Low Intermediate High
IC ‘‘Down’’ 49 60 45 28 39 24 23 15 15
‘‘Up’’ 26 41 74 7 11 25 4 5 20
p-Value 0.0002 0.002 0.001
EXP ‘‘Down’’ 71 86 82 26 35 20 18 20 25
‘‘Up’’ 4 15 37 9 15 29 9 0 10
p-Value ,0.0001 0.0002 0.006
For each major cohort where grade information was available, we give the grade distribution of the tumours across the ‘‘upregulated’’ and ‘‘downregulated’’ EMT clusters as predicted by
hierarchical clustering over the matrices Sgk Aks (IC) and Xgs (EXP), where g denotes the genes of the EMT pathway which are also in the selected feature set of the EMT-enriched
independent component k, and s denotes the samples. Tabulated p-values were computed using Fisher’s test.
doi:10.1371/journal.pcbi.0030161.t003
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MSigDB database), which conﬁrmed that the independent
components were not capturing transcriptional programs
localised to speciﬁc chromosomal regions. Instead, we believe
that the inferred independent components encapsulate ‘‘net’’
transcriptional programs that act globally and downstream of
the epigenetic and genetic modiﬁcations underlying cancer.
We also found that ICA components were associated more
often with known breast cancer phenotypes, including
clinical outcome, and that these associations were also much
stronger for ICA than for PCA. While this result is to be
expected, since ICA components map closer to pathways that
have been characterised using phenotypic information, one
should also bear in mind that these pathways were derived
from independent experiments; hence, the stronger associa-
tions between components, pathways, and phenotypes as
revealed by ICA provides a validation, not only of the
algorithm itself, but also of the characterised pathways.
Another important observation was the presence of multi-
ple components showing an association with a particular
pathway, regulatory module, or phenotype. This suggests that
a signiﬁcant proportion of pathways are part of multiple
biological processes. Alternatively, the presence of multiple
components enriched for a given pathway may reﬂect distinct
gene subset selection, which in turn suggests that the
pathways in MSigDB and NETPATH may need to be reﬁned
further. In the context of phenotypes, the presence of
multiple components correlating with ER status, grade, or
outcome, is suggestive of tumour heterogeneity, since, more
often than not, the differential distribution of the phenotype
across samples is dependent on the precise component.
Hence, the ﬁngerprint patterns of pathway activation derived
from ICA could potentially form the basis for further
clinically relevant deﬁnitions of breast cancer subtypes.
In an exploratory analysis, ICA revealed many interesting
associations between pathways and phenotypes that can form
the basis for future investigations. While all methods were
able to identify the expected relationships of the estrogen-
signalling pathway with ER status and cell-cycle pathway with
histological grade, ICA clearly outperformed PCA and KM-
clustering in identifying many other biologically relevant
associations (Figure 7). For example, ICA consistently found
an expression mode involving immune response pathways
that was upregulated in ER versus ERþ tumours. Thus, while
the relation between immune response and ER status is still
poorly understood [50], our results clearly point at an
important link between the immune response and estrogen
signalling in breast cancer, which needs to be explored
further. ICA also revealed interesting associations of the
Figure 7. Inter-Method Comparison of Selected Associations of Pathways and Regulatory Modules with Breast Cancer Phenotypes
The ability of the various methods to capture novel biological associations between pathways/regulatory modules and phenotypes is represented as a
binary heatmap across methods and cohorts. (A) Immune response pathway and ER status, (B) EMT-pathway and grade, (C) IRF and ER status, (D)
Neurofibromin-1 and clinical outcome. Black denotes a statistically significant association between a pathway/regulatory module and the phenotype in
question, white means no evidence of an association.
doi:10.1371/journal.pcbi.0030161.g007
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EMT-signalling, cell-adhesion, and MMP pathways with
histological grade and clinical outcome. Speciﬁcally, we
found a component upregulating EMT genes in high-grade
versus low-grade tumours, and which was statistically signiﬁ-
cant in three major cohorts. The association between the
activity level of the cell-adhesion and MMP pathways with
clinical outcome as revealed by ICA is also noteworthy given
that supervised approaches tend to only ﬁnd genes related to
cell-cycle pathways, as these are the strongest predictors of
grade and outcome. While the association of cell-adhesion
genes with outcome has been noted before in breast cancer
[29] and to a lesser extent in gastric cancer [51], here we show
that this result holds for a speciﬁc pathway and across several
breast cancer cohorts. ICA, in contrast to PCA and KM-
clustering, also identiﬁed interesting associations between
transcription factor modules and phenotypes (Figure 7). For
instance, it found strong associations between the IRF and ER
status and between NF1 and clinical outcome, as well as an
association between NFAT and outcome (Figure 4). These
associations are plausible given that changes in NFAT have
been shown to alter the metastatic and growth properties of
breast cancer cells [42–44], and given the important role NF1
and IRF play in breast cancer generally [52–56].
It could be argued that both IR- and cell-adhesion pathways
are differentially activated across tumours merely as a result
of lymphocytic or stromal contamination, respectively.
However, microarray studies proﬁling breast cancer cell lines
(BCL) have shown that genes associated with IR- and cell-
adhesion functions are also differentially regulated across cell
lines [25,57]. In particular, it was shown that genes related to
cell-adhesion functions were overexpressed in ER compared
with ERþ cell-lines [57]. While the study in [57] did not
explicitly mention the differential expression of immune
response genes, we veriﬁed, by applying ICA to this set of only
31 breast cancer cell lines (BCL), that an independent
component enriched for immune response genes was present
and that it correlated with the ER status of the cell lines
(Figure S6). This provided further validation of the link
between differential regulation of immune response path-
ways with the ER status of breast cancer cells, while also
simultaneously conﬁrming that the differential regulation of
these genes across the tumour set is not necessarily related to
varying degrees of lymphocytic inﬁltration.
Generally, we found that genes selected in the same
independent component showed a relatively strong co-
expression pattern (Figure 5B). It follows that ICA compo-
nents can often be given a biological interpretation similar to
that of clusters inferred through, say, hierarchical or k-means
clustering. To illustrate this with another example, we
considered the case of estrogen signalling and ER status.
This showed that clustering over the genes selected in an IC
that was associated with estrogen signalling and ER status
yielded similar heatmaps for the measured expression matrix
and the IC submatrix, and, furthermore, for both heatmaps
the association with the phenotype was evident (Figure S7).
On the other hand, ICA also found ‘‘non-trivial’’ associa-
tions, such as the association of the EMT pathway with grade
(Figure 6A), where the functional relationship of the genes in
the same pathway was not as evident from the gene
expression matrix (Figure 6B). Given that genes are shared
by multiple pathways, the functional relationship of the genes
may indeed not manifest itself as a strong co-expression
pattern. Thus, it would appear that ICA, through the
statistical independence criterion, which effectively uses
non-linear correlation measures (as opposed to mere linear
co-expression) to determine common functionality, is able to
capture non-trivial functional relationships of genes in a
common pathway, in spite of the fact that these genes may
not exhibit strong co-expression.
In summary, this work is the ﬁrst to our knowledge to
validate the ICA paradigm using a framework based on
existing pathway-knowledge and regulatory-module data-
bases. Moreover, it conﬁrms the added value of ICA over
PCA and clustering-based methods in identifying novel
associations of known pathways and regulatory modules with
breast cancer phenotypes. Our results also indicate that
larger datasets may be required before a more complete
Figure 8. Association Networks
Average association networks shown for ER status (A) and clinical
outcome (B). Only edges between phenotypes, pathways, and tran-
scription factors are shown (for the sake of clarity, edges between any
two pathways, transcription factors, or phenotypes are not shown). An
edge between two nodes was defined if the association between the
two nodes was present in at least three out of the four studies, as
predicted by the KernelICA algorithm. The diagrams are colour-coded as
follows: phenotype (red), pathways (green), and transcription factors/
binding motifs (blue).
INFLR, inflammatory response; TM, tyrosine metabolism.
doi:10.1371/journal.pcbi.0030161.g008
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understanding of the ICA model in the gene expression
context can be obtained, as well as to understand to what
degree ICA can help in deﬁning a more clinically relevant
molecular taxonomy of breast cancer.
Materials and Methods
A pathway-knowledge database. To test the ICA model, we ﬁrst
generated a comprehensive list of pathways, most of which are known
to be directly or indirectly involved in cancer biology. To compile
this list, we used the Molecular Signatures Database MSigDB [24],
which included 522 distinct pathways curated from the literature and
from other databases such as KEGG (http://www.genome.jp/kegg/) and
CGAP (http://cgap.nci.nih.gov/). We augmented this list with known
oncogenic pathways recently derived in [35] and cancer-signalling
pathways from NETPATH (http://www.netpath.org), yielding a total of
536 pathways. Not all of these pathways had sufﬁcient representation
across the six major studies. Speciﬁcally, out of these 536 pathways,
277 had at least ﬁve genes represented on each of the six microarray
platforms (probes on speciﬁc microarrays were also ﬁltered based on
quality, which explains why there wasn’t a higher percentage of
pathway gene lists with sufﬁcient representation). The full list of
pathways used are summarised in Table S1 in terms of their
representation on each of the arrays.
Regulatory motifs. We used the sequence-derived regulatory
motifs in human promoters and 39 UTRs from [36]. For each such
motif we deﬁned the associated regulatory gene module as the set of
genes having this motif in their promoters or 39 UTR, as provided in
MSigDB [24]. The selected feature sets of the inferred components
were tested for enrichment of regulatory modules, which provided us
with putative links between components and the transcription factors
that bind to these motifs.
The ICA and PCA Models. Brieﬂy, we review the ICA model [58] as
used in this work. Let Xgs denote the normalised data matrix of
expression values where g¼ 1,. . .,n denotes the genes and s¼ 1,. . . ,N
denotes the samples. We assume further that X has been normalised
so that the mean of each column of X is zero. Then ICA (or PCA)
produces an approximate decomposition of the matrix X into the
product of two matrices S (the ‘‘source’’ matrix) and A (the ‘‘mixing’’
matrix):
Xgs ¼
XK
k¼1
SgkAks þ Egs ð2Þ
where K  minfn,Ng is the number of components to be computed.
When K is strictly smaller than minfn,Ng, it is in general impossible to
pick S and A such that the error matrix vanishes. Therefore, the
algorithms aim at making E as small as possible, usually in the least
squares sense. This condition on E still leaves much leeway to select
the matrices S and A.
PCA consists of identifying an orthonormal matrix S (i.e.,Pn
g¼1 SgkSgk9 ¼ 0 for all k 6¼ k9, and
Pn
g¼1 SgkSgk ¼ 1 for all k) and
an orthogonal matrix A (i.e.,
PN
s¼1 AksAk9s ¼ 0 for all k 6¼ k9) so that
the data covariance matrix is diagonalised. In comparison, most ICA
algorithms start with a preprocessing step, in which the means of the
columns of X are set to zero, followed by a PCA. Thus, as with PCA
itself, this ﬁrst requires an orthonormal matrix S9 and an orthogonal
matrix A9 such that X ¼ S9A9 þ E9. It should be noted that
orthonormality of S9 implies a sample covariance between the
columns of S9 that equals zero. The ICA step per se amounts to then
ﬁnding a transformation W of S9,
Sgk ¼
XK
j¼1
S9gjWjk ð3Þ
such that the columns of S are ‘‘as independent as possible’’. Most ICA
methods consider that the zero covariance property of S9 is
compatible with this goal, hence they preserve this property in S9
by restricting W to the set of K3K orthogonal transformations. The
ICA algorithms, thus, search for an orthogonal matrix W that
maximises the statistical independence of the columns of S9. The
mixing matrix ﬁnally equals
Aks ¼
XK
j¼1
WjkA9js ð4Þ
and the error E is identical to E9.
A quantitative measure of independence between measurements
of random variables, in this case the columns of S9, is provided by a
contrast function. The only requirement on the contrast function is
that it goes with probability one to a prescribed extremum (usually
zero) if and only if the random variables are statistically independent
and as the number of measurements n goes to inﬁnity. This leaves
many possibilities for the contrast function, leading to a variety of
ICA algorithms, which may also differ in the numerical algorithm
used for the optimisation procedure. Here, we considered four
different ICA algorithms, which are described in more detail in
Protocol S1: the JADE (or ‘‘JointDiag’’) algorithm [59], the ‘‘FastICA’’
algorithm [31], the ‘‘KernelICA’’ algorithm [32], and the ‘‘RADICAL’’
algorithm [33].
Estimating the number of independent components. The estima-
tion of the number of sources in ICA is a hard outstanding problem.
While approaches to estimating the number of sources exist, for
example, the Bayesian Information Criterion (BIC) in a maximum
likelihood framework [34] or using the evidence bound in a
variational Bayesian approach [60–62], we decided to infer the same
number of components for each algorithm. There are two reasons for
this. First, because of the still relatively small sample sizes of
microarray experiments, estimating the correct number of compo-
nents is difﬁcult. It has therefore been conventional to use a ﬁxed
number of components [15,16]. Second, since the aim with our work
was to provide a comparison between the PCA-derived components
and those derived from ICA algorithms, using the same number of
components for each algorithm facilitated such a comparison.
Feature selection. For each component that is inferred, ICA and
PCA yield a corresponding list of genes and signed weights. The ICA
model is based on the premise that ICA modes selectively pick out a
small percentage of genes (;1%) that are strongly activated or
repressed in response to the deregulation of a particular pathway,
while the great majority of genes are unaffected. Mathematically, the
distribution of inferred weights must be non-gaussian, and in the
gene expression context they must be supergaussian (or leptokurtic),
since most of the genes in a mode belong to a gaussian component
centred at zero. Thus, to ﬁnd the genes that are differentially
activated, it is conventional to set a threshold, typically two or three
standard deviations from the mean, and to pick out those genes
whose absolute weights exceed this threshold. Although a more
elegant method for determining an appropriate threshold, and which
is based on measuring the deviation from normality of the weight
distributions, is available [20], this method is not applicable to PCA
components where deviation from normality is not a requirement.
Hence, since the main aim was to provide an objective comparison of
ICA with PCA, we decided to use the threshold method as this
method would yield approximately the same number of features per
component for PCA and ICA. To focus on the pathways that
dominate an ICA mode, we used the more stringent threshold of 3
sigma on either side from the zero mean, which picks out the 0.2% of
genes in the tails of the signed weight distributions. Robustness of our
results to the choice of threshold was evaluated by considering less
stringent thresholds of 2 and 2.5 sigma. Thus, for each inferred ICA
mode or principal component, we obtained a list of selected features
and associated signed weights. This resulted in a mean number of
approximately 160 features (3 sigma threshold) selected per
component, although this number varied signiﬁcantly depending
on study. Importantly though, while ICA algorithms did generally
capture more features per component than PCA (as we would expect
since ICA algorithms seek supergaussian components), the difference
in selected feature numbers was not signiﬁcant (Table S2).
K-means clustering methods: MVG-KM and PCA-KM. To provide
an objective comparison of ICA/PCA with clustering methods, the
clustering step was preceded by a feature selection step which
ensured that all methods selected an approximately equal number of
genes. This feature selection step was performed in two different
ways. For a given cohort, genes were ﬁrst ranked according to their
expression variance across samples. In the most-variable-genes
(MVG) method, the top 15% variable genes were then selected. In
the second method, we used all the distinct genes selected through
PCA using the 3 sigma threshold. Since this number is less than the
total number (i.e., not distinct) of features selected from the PCA
components, the remaining distinct genes were selected from the
ranked MVG list. Having selected the features via one of the above
methods, clustering was then performed using a robust version of k-
means clustering, known as partitioning around medoids [63], where
k was set to 10 in order to match the number of components
inferred by ICA and PCA. Thus, PCA-KM selected the same number
of total features as PCA and approximately the same number as ICA,
while the threshold of 15% was chosen to ensure that MVG-KM did
not select less total number of features than ICA or PCA (Table S2).
Enrichment analysis. For the genes selected in a ICA or PCA
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component or for the genes in a given cluster derived from either
MVG-KM or PCA-KM, enrichment analysis evaluates whether there is
statistically signiﬁcant enrichment of genes from a given pathway or
regulatory module. For a given study s and inference method m, let i
denote a given inferred component (or cluster) and p a pathway (or
regulatory module). In what follows, we also use ‘‘component’’ to
refer to the clusters of the KM-algorithms, and also use ‘‘pathway’’ to
refer to the regulatory modules. Let NS denote the number of genes
on the array of data set s, and nsp denote the number of genes from
pathway p on that same array. Similarly, let dsmi denote the number of
genes selected in component i, and tsmi the number of genes from
pathway p among the selected dsmi features. Then, under the null
hypothesis, where the selected genes are chosen randomly, the
number tsmi follows a hypergeometric distribution. Speciﬁcally, the
probability distribution is
PðtÞ ¼ dsmi
t
  Yt1
j¼0
nsp  j
Ns  j
 ( ) Ydsmit1
j¼0
ðNs  nspÞ  j
ðNs  tÞ  j ¼
nsp
t
 
Ns nsp
dsmi t
 
Ns
dsmi
 
ð5Þ
and a p-value can be readily computed as P(t . tsmi). Note that
Vandermonde’s identity implies that the probability distribution is
correctly normalised. Thus, for a given study and method, we can
compute a p-value for each component-pathway pair that evaluates
how enriched the component is in terms of genes from that
particular pathway. To correct for multiple testing, we used the
Benjamini-Hochberg procedure [64] and called a component–path-
way pair association signiﬁcant if the p-value was less than a threshold
determined by setting the false discovery rate (FDR) equal to 0.05.
Supporting Information
Figure S1. The PEI for All Breast Cancer Cohorts
The pathway enrichment index, PEI, for all seven breast cancer
cohorts in Table 1.
Found at doi:10.1371/journal.pcbi.0030161.sg001 (2 KB PDF).
Figure S2. Vijver
For the breast cancer cohort ‘‘Vijver’’, we provide a heatmap of
association between components/clusters and the most commonly
enriched pathways and regulatory modules, as well as the association
heatmap between components/clusters and breast cancer pheno-
types. The strength of association between a component/cluster and a
phenotype is colour-coded as follows: p , 1010 (dark red) p , 0.001
(red), p , 0.01 (orange), p , 0.05 (pink), and p . 0.05 (white).
Enriched component-pathway and component-regulatory module
pairs are colour-coded in red.
Found at doi:10.1371/journal.pcbi.0030161.sg002 (171 KB PDF).
Figure S3. Wang
For the breast cancer cohort ‘‘Wang’’, we provide a heatmap of
association between components/clusters and the most commonly
enriched pathways and regulatory modules, as well as the association
heatmap between components/clusters and breast cancer pheno-
types. The strength of association between a component/cluster and a
phenotype is colour coded as follows: p , 1010 (dark red) p , 0.001
(red), p , 0.01 (orange), p , 0.05 (pink), and p . 0.05 (white).
Enriched component-pathway and component-regulatory module
pairs are colour-coded in red.
Found at doi:10.1371/journal.pcbi.0030161.sg003 (162 KB PDF).
Figure S4. Naderi
For the breast cancer cohort ‘‘Naderi’’, we provide heatmaps of
association between components/clusters and the most commonly
enriched pathways and regulatory modules, as well as the association
heatmap between components/clusters and breast cancer pheno-
types. The strength of association between a component/cluster and a
phenotype is colour coded as follows: p , 1010 (dark red) p , 0.001
(red), p , 0.01 (orange), p , 0.05 (pink), and p . 0.05 (white).
Enriched component-pathway and component-regulatory module
pairs are colour-coded in red.
Found at doi:10.1371/journal.pcbi.0030161.sg004 (162 KB PDF).
Figure S5. JRH-2
For the breast cancer cohort ‘‘JRH-2’’, we provide heatmaps of
association between components/clusters and the most commonly
enriched pathways and regulatory modules, as well as the association
heatmap between components/clusters and breast cancer pheno-
types. The strength of association between a component/cluster and a
phenotype is colour coded as follows: p , 1010 (dark red) p , 0.001
(red), p , 0.01 (orange), p , 0.05 (pink), and p . 0.05 (white).
Enriched component-pathway and component-regulatory module
pairs are colour-coded in red.
Found at doi:10.1371/journal.pcbi.0030161.sg005 (168 KB PDF).
Figure S6. Association of Immune Response with ER Status in a Cell
Line Dataset
Boxplot showing the distribution of weights from an independent
component enriched for immune response genes across the basal,
luminal, and mesenchymal cell–line subtypes, as deﬁned in [57]. The
p-value of a Wilcoxon-rank sum test between the basal and luminal
subtypes is given.
Found at doi:10.1371/journal.pcbi.0030161.sg006 (3 KB PDF).
Figure S7. Association of Estrogen Signalling with ER Status
(A) For each major breast cancer cohort, we give the heatmap of
component expression values for a component enriched for the
estrogen-signalling pathway, i.e., the heatmap matrix shown is SgkAks
where k is the component enriched for the estrogen-signalling
pathway, g is any gene found on the array that is also in the pathway
and in the selected feature set of the component, and s denotes the
tumour sample. The ICA algorithm for which this heatmap is shown
is the KernelICA algorithm. Samples have been ordered according to
a k-means clustering over the set of genes. Blue denotes ‘‘upregula-
tion’’, yellow ‘‘downregulation’’.
(B) For each major breast cancer cohort, we give the heatmap of
expression values for the same set of genes as in (A). Thus, the
heatmap matrix shown is Xgs where Xgs denotes the measured
expression level of gene g in sample s. As before, samples have been
ordered according to a k-means clustering over the represented
genes.
CL, cluster labels from 2-means clustering; ER, ER status (black, ER;
grey, ERþ). Red denotes relative overexpression, green underexpres-
sion.
Found at doi:10.1371/journal.pcbi.0030161.sg007 (235 KB PDF).
Protocol S1. PCA and ICA Algorithms
Found at doi:10.1371/journal.pcbi.0030161.sd001 (98 KB PDF).
Table S1. Number of Genes per Pathway and Numbers Present on
Array Platforms
Found at doi:10.1371/journal.pcbi.0030161.st001 (26 KB TXT).
Table S2. Average Number of Selected Genes per Component/Cluster
for Each Cohort and Method and Corresponding Average Number of
Distinct Genes Captured by the Ten Components/Clusters
Found at doi:10.1371/journal.pcbi.0030161.st002 (0 KB TXT).
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